- Home
- JANX vs KURA Comparison
JANX vs KURA Comparison
Compare JANX & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JANX | KURA |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 840.4M | 841.6M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | JANX | KURA |
|---|---|---|
| Price | $14.64 | $10.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $47.00 | $25.56 |
| AVG Volume (30 Days) | 845.1K | ★ 1.8M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,000,000.00 | ★ $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | N/A | $106.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $12.12 | $5.45 |
| 52 Week High | $35.34 | $12.49 |
Technical Indicators
Market Signals| Indicator | JANX | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 59.43 | 66.10 |
| Support Level | $13.13 | $8.72 |
| Resistance Level | $15.49 | $11.29 |
| Average True Range (ATR) | 0.57 | 0.48 |
| MACD | 0.15 | 0.17 |
| Stochastic Oscillator | 84.78 | 86.59 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.